GB001 in Adult Subjects With Moderate to Severe Asthma
Status:
Completed
Trial end date:
2020-08-18
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo-controlled, dose-ranging, multi-center study to evaluate
the efficacy and safety of GB001 when added to standard-of care (SOC) asthma maintenance
therapy in adults with moderate to severe asthma and an eosinophilic phenotype with respect
to asthma worsening at the end of 24 weeks of treatment.
Phase:
Phase 2
Details
Lead Sponsor:
GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.